These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. Molecular targets for therapy in systemic sclerosis. Iwamoto N; Distler O Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S19. PubMed ID: 23259845 [TBL] [Abstract][Full Text] [Related]
69. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. McGaugh S; Kallis P; De Benedetto A; Thomas RM Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019 [TBL] [Abstract][Full Text] [Related]
70. Targeted delivery in scleroderma fibrosis. Varrica C; Dias HS; Reis C; Carvalheiro M; Simões S Autoimmun Rev; 2021 Feb; 20(2):102730. PubMed ID: 33338593 [TBL] [Abstract][Full Text] [Related]
71. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Young A; Khanna D Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190 [TBL] [Abstract][Full Text] [Related]
72. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Tsou PS; Varga J; O'Reilly S Nat Rev Rheumatol; 2021 Oct; 17(10):596-607. PubMed ID: 34480165 [TBL] [Abstract][Full Text] [Related]